Dr. Reddy's Laboratories Limited — Investor Meet, 29-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Reddy's Q1FY26 revenues hit ₹8,545 Cr (+11% YoY) with EBITDA margin at 26.7% and PAT at ₹1,419 Cr (+2% YoY). US generics were soft, impacted by Lenalidomide, but European and India businesses grew strongly. Future growth hinges on key launches: generic Semaglutide (Ozempic) in Canada targeted for early 2026 with 10-12M pen capacity, and biosimilar Abatacept in late 2026/early 2027. With a strong ₹2,922 Cr net cash, the company invests in pipeline assets, new markets, and efficiency, exploring acquisitions. Management is confident in navigating dynamics for sustained growth.